Exclusive Summary

• First-in-class dual-target mechanism (VMAT2 inhibitor & Sigma-1 Receptor agonist) that combines rapid symptom control with long-term pathological modification for Tardive Dyskinesia (TD).
• Best-in-class efficacy potential with preliminary Phase II data showing 44% of patients achieving ≥50% AIMS score reduction (vs 28% for current SOC), plus persistent effect post-discontinuation.
• Overcomes critical SOC limitations: Drug exposure is completely void of CYP2D6 polymorphism impacts, avoiding life-threatening extrapyramidal and psychiatric off-target side effects.
• Immense commercial and out-licensing value: Targets a highly lucrative $3.9 billion SOC market with global IP coverage (PCT filed, patents granted in JP/CN, US Notice of Allowance issued).

Asset Materials

Contact Us for Full Materials